Previous 10 | Next 10 |
Michael Burry predicted the mortgage collapse and made huge profits as profiled in the movie "The Big Short." Last year he was very early to GameStop, earning significant profits. He added a number of bearish bets on interest rates (and Tesla!). Dipped his toes into shipping. ...
Marinus Pharmaceuticals, Inc. (MRNS) Q1 2021 Earnings Conference Call May 17, 2021 08:30 ET Company Participants Sasha Damouni - Vice President, Investor Relations and Corporate Communications Scott Braunstein - Chief Executive Officer Joe Hulihan - Chief Medical Officer Christy Shafer - Chie...
The following slide deck was published by Marinus Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Marinus Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
Marinus Pharmaceuticals (MRNS): Q1 GAAP EPS of -$0.74 misses by $0.29.Revenue of $1.81M misses by $0.75M.Cash, cash equivalents, and investments of $123.5M.The company believes its cash and cash equivalents as of March 31, 2021 combined with the net upfront proceeds of the Oaktree credit faci...
Strategic credit financing agreement with funds managed by Oaktree Capital Management, L.P. (“Oaktree”) will provide up to $125 million to support continued development and commercial readiness of both the oral and IV ganaxolone programs On track to submit NDA for us...
New Date and Time: Monday, May 17 at 8:30 AM Eastern Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it has rescheduled its Fiscal First Quart...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it plans to release financial results for the first quarter ended March 31, 2021 after the market close on ...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following virtual investor conferences: B. Ri...
Marinus Pharmaceuticals (MRNS) trades 1.2% higher premarket after appointing Steven E. Pfanstiel as Chief Financial Officer and Lisa Lejuwaan to the newly created position of VP, Sales.The appointments indicate the company's planning for potential comme...
J&J veteran Steven Pfanstiel named as Chief Financial Officer Lisa Lejuwaan to build out launch strategy as Vice President of Sales Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics ...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...